Abstract
Lenalidomide (LEN) is an immunomodulatory drug (IMiD) which exerts tumoricidal effects and has immunomodulatory, anti-inflammatory and anti-angiogenic properties that synergistically keep the tumor in remission. It is currently approved as second-line therapy for multiple myeloma (MM) and for 5q defective myelodysplastic syndrome, while ongoing studies are at present evaluating its role in both solid and hematologic malignancies. Based on its high activity as an anti-myeloma drug with a good tolerability profile, LEN is currently gaining interest in both preclinical and clinical research for combinatory treatments with novel agents including monoclonal antibodies, immunotoxins, tyrosine kinase inhibitors, new proteasome inhibitors and epigenetic-interfering agents as well as with new compounds targeting the cancer stem cell niche. Preliminary data from clinical studies are encouraging and suggest a favorable safety profile, although the long-term tolerability of these combinatory regimens needs to be carefully evaluated since an increased incidence of new primary tumors associated with LEN treatment has recently been reported. Thus, from bench to bedside studies are required to design clinical trials for new drug combination approval.
| Original language | English |
|---|---|
| Pages (from-to) | 9-20 |
| Number of pages | 12 |
| Journal | Critical Reviews in Oncology/Hematology |
| Volume | 85 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2013 |
Fingerprint
Keywords
- Bone resorption
- Combination therapies
- IMiDs
- Lenalidomide
- Multiple myeloma
- New drugs
ASJC Scopus subject areas
- Oncology
- Hematology
- Geriatrics and Gerontology
Cite this
Novel lenalidomide-based combinations for treatment of multiple myeloma. / Cives, Mauro; Simone, Valeria; Brunetti, Oronzo; Longo, Vito; Silvestris, Franco.
In: Critical Reviews in Oncology/Hematology, Vol. 85, No. 1, 01.2013, p. 9-20.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Novel lenalidomide-based combinations for treatment of multiple myeloma
AU - Cives, Mauro
AU - Simone, Valeria
AU - Brunetti, Oronzo
AU - Longo, Vito
AU - Silvestris, Franco
PY - 2013/1
Y1 - 2013/1
N2 - Lenalidomide (LEN) is an immunomodulatory drug (IMiD) which exerts tumoricidal effects and has immunomodulatory, anti-inflammatory and anti-angiogenic properties that synergistically keep the tumor in remission. It is currently approved as second-line therapy for multiple myeloma (MM) and for 5q defective myelodysplastic syndrome, while ongoing studies are at present evaluating its role in both solid and hematologic malignancies. Based on its high activity as an anti-myeloma drug with a good tolerability profile, LEN is currently gaining interest in both preclinical and clinical research for combinatory treatments with novel agents including monoclonal antibodies, immunotoxins, tyrosine kinase inhibitors, new proteasome inhibitors and epigenetic-interfering agents as well as with new compounds targeting the cancer stem cell niche. Preliminary data from clinical studies are encouraging and suggest a favorable safety profile, although the long-term tolerability of these combinatory regimens needs to be carefully evaluated since an increased incidence of new primary tumors associated with LEN treatment has recently been reported. Thus, from bench to bedside studies are required to design clinical trials for new drug combination approval.
AB - Lenalidomide (LEN) is an immunomodulatory drug (IMiD) which exerts tumoricidal effects and has immunomodulatory, anti-inflammatory and anti-angiogenic properties that synergistically keep the tumor in remission. It is currently approved as second-line therapy for multiple myeloma (MM) and for 5q defective myelodysplastic syndrome, while ongoing studies are at present evaluating its role in both solid and hematologic malignancies. Based on its high activity as an anti-myeloma drug with a good tolerability profile, LEN is currently gaining interest in both preclinical and clinical research for combinatory treatments with novel agents including monoclonal antibodies, immunotoxins, tyrosine kinase inhibitors, new proteasome inhibitors and epigenetic-interfering agents as well as with new compounds targeting the cancer stem cell niche. Preliminary data from clinical studies are encouraging and suggest a favorable safety profile, although the long-term tolerability of these combinatory regimens needs to be carefully evaluated since an increased incidence of new primary tumors associated with LEN treatment has recently been reported. Thus, from bench to bedside studies are required to design clinical trials for new drug combination approval.
KW - Bone resorption
KW - Combination therapies
KW - IMiDs
KW - Lenalidomide
KW - Multiple myeloma
KW - New drugs
UR - http://www.scopus.com/inward/record.url?scp=84870800589&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870800589&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2012.06.008
DO - 10.1016/j.critrevonc.2012.06.008
M3 - Article
VL - 85
SP - 9
EP - 20
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
IS - 1
ER -